Ind-Ra upgrades rating of Sequent Scientific Limited equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
BUY Adani Enterprises Limited | Target: Rs 1,240 | Stop loss: Rs 1,050 ADANIENT is in a secular uptrend, trading in a cycle of higher highs and higher bottoms, indicating inherent strength in the overall counter. On the daily time frame, the stock has rebounded from its 21-DEMA, and sustaining above this, is expected to march with the same tandem. Also, the mean of the Bollinger band has historically proven strong support for the counter making it a favourable risk-reward ratio for a short-term duration.
BUY Sequent Scientific Limited | Target: Rs 274 | Stop loss: Rs 232 SEQUENT has seen some minor correction from the lifetime highs in recent times and has managed to sustain at higher levels post support of its 21-DEMA on the daily time frame, which was also the consolidation zone for the stock in the past. Even on the oscillator front, the 14 period RSI has rebounded to witness a positive crossover and is all set to march northwards, reassuring the strong trend in the counter.
SeQuent announced launch of Citramox® LA in EU
Posted On: 2020-12-10 02:24:52 (Time Zone: Arizona, USA)
SeQuent Scientific Limited (SeQuent), announced launch of Citramox® LA 150 mg/ml Suspension Injection for Cattle and Pigs in 10 European countries, including the key markets of Western Europe. The product has recently received approval through its Spanish subsidiary Laboratorios Karizoo, S.A., and will be the first Long-Acting injectable to be offered by SeQuent in Europe.
This new approval for SeQuent builds on the recent approvals of Tulazzin® (Tulathromycin) and Halofusol® (Halofuginone) in Europe. All these approvals have been received within 12 months of filing, which reflects on SeQuent s growing strengths in introducing new products for the regulated markets.